Literature DB >> 30236630

Benefit of Eculizumab Compared to Standard of Care Still Unproven in C3 Glomerulopathy.

Caroline Duineveld1, Nicole C A J van de Kar2, Jack F M Wetzels1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30236630     DOI： 10.1053/j.ajkd.2018.07.013

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  1 in total

1.  Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.

Authors:  Marloes A H M Michels; Kioa L Wijnsma; Roel A J Kurvers; Dineke Westra; Michiel F Schreuder; Joanna A E van Wijk; Antonia H M Bouts; Valentina Gracchi; Flore A P T Engels; Mandy G Keijzer-Veen; Eiske M Dorresteijn; Elena B Volokhina; Lambertus P W J van den Heuvel; Nicole C A J van de Kar
Journal:  Pediatr Nephrol       Date:  2021-09-02       Impact factor: 3.714
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.